These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27665287)

  • 61. Worm infestations and development of autoimmunity in children - The ABIS study.
    Ludvigsson J; Jones MP; Faresjö Å
    PLoS One; 2017; 12(3):e0173988. PubMed ID: 28333965
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of palivizumab in children with congenital heart disease.
    Paediatr Child Health; 2003 Dec; 8(10):631-6. PubMed ID: 20019858
    [No Abstract]   [Full Text] [Related]  

  • 63. Question 1: Palivizumab for all children with Down syndrome?
    Huggard D; Molloy EJ
    Arch Dis Child; 2019 Jan; 104(1):94-97. PubMed ID: 30279156
    [No Abstract]   [Full Text] [Related]  

  • 64. [Thesaurisms in the child].
    SALDUN DE RODRIGUEZ ML; PELUFFO E; VOLPE A
    Arch Pediatr Urug; 1949 Jul; 20(7):409-50. PubMed ID: 18136799
    [No Abstract]   [Full Text] [Related]  

  • 65. Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus.
    Killikelly AM; Kanekiyo M; Graham BS
    Sci Rep; 2016 Sep; 6():34108. PubMed ID: 27682426
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Seasonal variability of respiratory syncytial virus infection in the Top End of the Northern Territory (2012-2014).
    Fagan P; McLeod C; Baird RW
    J Paediatr Child Health; 2017 Jan; 53(1):43-46. PubMed ID: 27671992
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gut Microbiota and Risk of Developing Celiac Disease.
    Cenit MC; Codoñer-Franch P; Sanz Y
    J Clin Gastroenterol; 2016; 50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015():S148-S152. PubMed ID: 27741161
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Quality of Life in Type 1 Diabetes and Celiac Disease: Role of the Gluten-Free Diet.
    Pham-Short A; Donaghue KC; Ambler G; Garnett S; Craig ME
    J Pediatr; 2016 Dec; 179():131-138.e1. PubMed ID: 27720243
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.
    Melero JA; Mas V; McLellan JS
    Vaccine; 2017 Jan; 35(3):461-468. PubMed ID: 27692522
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Viruses and celiac disease: what do we know ?
    Cohen R; Mahlab-Guri K; Atali M; Elbirt D
    Clin Exp Med; 2023 Nov; 23(7):2931-2939. PubMed ID: 37103650
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Moving from nature to nurture: a systematic review and meta-analysis of environmental factors associated with juvenile idiopathic arthritis.
    Clarke SLN; Mageean KS; Maccora I; Harrison S; Simonini G; Sharp GC; Relton CL; Ramanan AV
    Rheumatology (Oxford); 2022 Feb; 61(2):514-530. PubMed ID: 34382060
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma.
    Igde M; Kabasakal H; Ozturk O; Karatekin G; Aygun C
    Minerva Pediatr; 2018 Jun; 70(3):252-259. PubMed ID: 29795072
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
    Nuijten MJ; Wittenberg W; Lebmeier M
    Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.
    Pignotti MS; Carmela Leo M; Pugi A; De Masi S; Biermann KP; Galli L; Vitali Rosati G; Buonocore G; Mugelli A; Dani C; Lucenteforte E; Bellini F; Donzelli G;
    Pediatr Pulmonol; 2016 Oct; 51(10):1088-1096. PubMed ID: 27618642
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study.
    Haerskjold A; Linder M; Henriksen L; Thomsen SF; Kieler H; Ravn H; Stensballe LG
    Paediatr Drugs; 2016 Dec; 18(6):435-441. PubMed ID: 27665287
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Palivizumab Exposure and the Risk of Atopic Dermatitis, Asthma and Allergic Rhinoconjunctivitis: A Cross-National, Population-Based Cohort Study.
    Haerskjold A; Stokholm L; Linder M; Thomsen SF; Bergman G; Berglind IA; Kieler H; Ravn H; Stensballe LG
    Paediatr Drugs; 2017 Apr; 19(2):155-164. PubMed ID: 28188494
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.